Your browser is no longer supported. Please, upgrade your browser.
Settings
ALDX Aldeyra Therapeutics, Inc. daily Stock Chart
ALDX [NASD]
Aldeyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.96 Insider Own2.20% Shs Outstand28.38M Perf Week-3.20%
Market Cap189.01M Forward P/E- EPS next Y-1.91 Insider Trans-13.42% Shs Float27.15M Perf Month-9.51%
Income-46.10M PEG- EPS next Q-0.50 Inst Own63.10% Short Float4.26% Perf Quarter-19.37%
Sales- P/S- EPS this Y-27.80% Inst Trans-3.79% Short Ratio1.87 Perf Half Y-29.82%
Book/sh2.90 P/B2.30 EPS next Y12.00% ROA-70.00% Target Price28.00 Perf Year-23.01%
Cash/sh2.89 P/C2.30 EPS next 5Y- ROE-80.00% 52W Range6.34 - 16.70 Perf YTD-19.76%
Dividend- P/FCF- EPS past 5Y-64.60% ROI- 52W High-60.12% Beta0.81
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low4.99% ATR0.31
Employees19 Current Ratio9.20 Sales Q/Q- Oper. Margin- RSI (14)39.90 Volatility4.82% 4.34%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.20% Profit Margin- Rel Volume0.35 Prev Close6.54
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume618.71K Price6.66
Recom1.50 SMA20-4.39% SMA50-12.69% SMA200-25.05% Volume214,054 Change1.83%
Dec-04-18Initiated Citigroup Buy $23
Sep-26-18Reiterated Cantor Fitzgerald Overweight $23 → $30
Sep-13-18Initiated Janney Buy
Jan-26-18Initiated Seaport Global Securities Buy $13
Sep-26-16Initiated H.C. Wainwright Buy $18
Jul-01-16Initiated Stifel Buy $16
Jul-01-15Initiated Canaccord Genuity Buy $16
Mar-25-15Initiated Chardan Capital Markets Buy $16
Mar-20-15Reiterated H.C. Wainwright Buy $13 → $14
Nov-18-14Initiated H.C. Wainwright Buy $13
Jun-19-14Initiated Aegis Capital Buy $35
May-30-19 08:00AM  Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 07:21PM  Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-09-19 03:23PM  Aldeyra Therapeutics Inc (ALDX) Q1 2019 Earnings Call Transcript Motley Fool
07:00AM  Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
May-02-19 08:00AM  Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019 PR Newswire
Apr-30-19 08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial PR Newswire
Apr-09-19 08:00AM  Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting PR Newswire
Apr-02-19 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease PR Newswire
Mar-27-19 05:09PM  Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge Zacks
10:00AM  Future Brightens for 2 Small Biotech Stocks TheStreet.com
Mar-26-19 01:14PM  Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today Motley Fool +35.99%
11:57AM  Aldeyra stock jumps 50 percent after eye allergy trial success American City Business Journals
10:37AM  Aldeyra's eye drug meets main goal in late-stage study, shares surge Reuters
09:41AM  Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit? Simply Wall St.
07:51AM  Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints MarketWatch
07:46AM  Aldeyra's eye drug meets main goal in late-stage study, shares surge Reuters
07:00AM  Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis PR Newswire
Mar-25-19 04:01PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis PR Newswire
Mar-13-19 10:35AM  Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock Zacks +5.50%
02:02AM  Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-08-19 12:12PM  Aldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Aldeyra Therapeutics Announces Year-End 2018 Financial Results PR Newswire
Mar-01-19 08:00AM  Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019 PR Newswire
Feb-28-19 07:00AM  Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day PR Newswire
Feb-12-19 08:00AM  Aldeyra Therapeutics to Host 2019 Research & Development Day PR Newswire
Jan-30-19 07:55AM  Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-29-19 08:00AM  Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision PR Newswire
Jan-15-19 08:00AM  Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations PR Newswire
Jan-03-19 08:00AM  Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer PR Newswire
Dec-20-18 10:33AM  Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial PR Newswire
Dec-17-18 09:42PM  Should You Buy Aldeyra Therapeutics Inc (ALDX)? Insider Monkey -6.77%
Nov-30-18 12:48PM  Should You Be Concerned About Aldeyra Therapeutics Incs (NASDAQ:ALDX) Historical Volatility? Simply Wall St.
Nov-28-18 08:00AM  Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference PR Newswire
Nov-14-18 07:00AM  Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results PR Newswire -11.50%
Nov-08-18 08:35AM  Recent Analysis Shows Freightcar America, Anworth Mortgage Asset, AMN Healthcare Services, Cenovus Energy, Dynex Capital, and Aldeyra Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-06-18 08:00AM  Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference PR Newswire
Nov-05-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results PR Newswire
Oct-16-18 02:46PM  Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-02-18 09:32AM  Mangrove Partners: Performance, AUM, and Holdings Insider Monkey
Sep-28-18 10:06AM  Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session Zacks
08:00AM  Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-27-18 08:00PM  Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock PR Newswire +7.49%
09:12AM  Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap Zacks
08:20AM  The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-26-18 04:01PM  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire +34.85%
12:54PM  Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results InvestorPlace
08:25AM  The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial Benzinga
08:12AM  Alderya's stock rockets after positive trial results of mesothelioma treatment MarketWatch
07:00AM  Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial PR Newswire
Sep-25-18 04:30PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial PR Newswire
08:00AM  Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer PR Newswire
Sep-06-18 08:52AM  Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options Zacks
Aug-17-18 08:20AM  Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-09-18 07:30AM  Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update PR Newswire
Aug-01-18 08:00AM  Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference PR Newswire
Jul-31-18 08:00AM  Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer PR Newswire
Jul-24-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial PR Newswire
Jul-12-18 08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial PR Newswire
Jun-26-18 08:00AM  Aldeyra Therapeutics Announces Development Programs at 2018 Research Day PR Newswire
Jun-25-18 04:01PM  Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes PR Newswire
Jun-20-18 08:00AM  Aldeyra Therapeutics Announces 2018 Research Day PR Newswire
May-30-18 07:45AM  Analysis: Positioning to Benefit within Aldeyra Therapeutics, Freightcar America, Bank of Hawaii, Heritage-Crystal Clean, Amedisys, and U.S. Global Investors Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-15-18 07:30AM  Aldeyra Therapeutics Announces First Quarter 2018 Financial Results PR Newswire
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-10-18 08:00AM  Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy PR Newswire
May-09-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results PR Newswire
May-01-18 07:00AM  Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting PR Newswire
Apr-24-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial PR Newswire
Apr-19-18 07:50AM  Free Post Earnings Research Report: Curis Quarterly Revenue Jumped 38.10% ACCESSWIRE
Apr-05-18 08:15AM  Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-29-18 07:30AM  Aldeyra Therapeutics Announces Year End 2017 Financial Results PR Newswire -7.98%
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-22-18 04:28PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results PR Newswire
Feb-27-18 08:00AM  Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases PR Newswire +12.34%
Feb-21-18 08:00AM  Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting PR Newswire +5.63%
Feb-09-18 08:15AM  New Research Coverage Highlights Carter's, Invacare, Hortonworks, BGC Partners, Hyatt Hotels, and Aldeyra Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-30-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial PR Newswire
Dec-14-17 03:55PM  Why Aldeyra Therapeutics Incs (NASDAQ:ALDX) CEO Pay Matters To You Simply Wall St.
Nov-29-17 08:00AM  Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting PR Newswire
Nov-09-17 01:05PM  Does Aldeyra Therapeutics Incs (ALDX) Debt Level Pose A Serious Problem? Simply Wall St.
07:30AM  Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results PR Newswire
Nov-07-17 08:00AM  Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference PR Newswire
Nov-02-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results PR Newswire
Oct-25-17 08:00AM  Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting PR Newswire
Oct-24-17 08:00AM  Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting PR Newswire
Oct-10-17 07:30AM  Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day PR Newswire
Oct-05-17 08:00AM  Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting PR Newswire
Oct-02-17 07:12PM  Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio? Simply Wall St.
Sep-27-17 09:46AM  /C O R R E C T I O N -- Aldeyra Therapeutics, Inc./ PR Newswire
Sep-21-17 04:01PM  Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares PR Newswire
Sep-20-17 08:00AM  Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-19-17 08:57AM  Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire -20.33%
Sep-18-17 04:01PM  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
02:04AM  [$$] Clinical Development News, Sept. 11-15 The Wall Street Journal
Sep-15-17 08:00AM  Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE -17.59%
Sep-13-17 09:00AM  Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session Zacks +12.39%
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase IIb clinical trial for the treatment of dry eye diseases, as well as Phase III clinical trial for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjogren-Larsson syndrome. Its portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative inflammatory diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. In addition, the company develops ADX-2191, an intravitreal dihydrofolate reductase inhibitor for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease; and ADX-1615, which inhibits Hsp90 for the treatment of various inflammatory diseases. Aldeyra Therapeutics, Inc. has a partnership with Janssen, a Johnson & Johnson company to develop RASP for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TREU JESSE IDirectorMar 26Sale10.0196,743968,3978,763Mar 28 05:10 PM